



PEI Pharmacare
P.O. Box 2000
Charlottetown, PE
C1A 7N8
www.princeedwardisland.ca



Programmes provinciaux de médicaments
C.P. 2000
Charlottetown, PE
C1A 7N8
www.princeedwardisland.ca

PEI Pharmacare Bulletin

Issue (2025-22)

November 4, 2025

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY **(EFFECTIVE DATE: NOVEMBER 18, 2025)**

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN	MFR
Aflibercept	Aflivu	2mg / 0.05mL	Pre-Filled Syringe Vial	02554178 02554194	APX
Criteria	See online Formulary for Aflibercept criteria.				
Program Eligibility	Financial Assistance Drug Program, High Cost Drug Program, Nursing Home Drug Program, Catastrophic Drug Program, Seniors Drug Program, Family Health Benefit Drug Program				

Aflibercept	Yesafili	2mg / 0.05mL	Pre-Filled Syringe Vial	02558238 02535858	BIL
Criteria	See online Formulary for Aflibercept criteria.				
Program Eligibility	Financial Assistance Drug Program, High Cost Drug Program, Nursing Home Drug Program, Catastrophic Drug Program, Seniors Drug Program, Family Health Benefit Drug Program				

CRITERIA UPDATE

Effective immediately, currently listed sitagliptin, sitagliptin/metformin, and sitagliptin/metformin XR products will no longer require Special Authorization and will be open benefit in the Diabetes Drug Program, Financial Assistance Drug Program, Nursing Home Drug Program, and Catastrophic Drug Program.

Effective immediately, all currently listed filgrastim biosimilars will be included as open benefits in the Transplant Drug Program. Existing coverage criteria will continue to apply to other applicable drug programs.

SUBMISSION OF SPECIAL AUTHORIZATION REQUESTS BY PHARMACISTS

Starting today, pharmacists will be permitted to submit Special Authorization Requests directly to PEI Pharmacare. For further details, please refer to the Pharmacare communication sent to community pharmacies on October 21, 2025.